The investigational microbiota-based live biotherapeutic RBX2660 (Rebiotix/Ferring Pharmaceuticals), which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of September, reduces recurrent Clostridioides difficile infections (rCDI), with most treatment responders remaining CDI-free for six to 24 months, according to data from five clinical trials.
The analysis included three phase 2 trials (PUNCH CD, PUNCH CD2 and PUNCH CD open-label)